CORRECTING and REPLACING AmerisourceBergen Authorizes a New $750 Million Share Repurchase Program and Approves Quarterly

  CORRECTING and REPLACING AmerisourceBergen Authorizes a New $750 Million
  Share Repurchase Program and Approves Quarterly Dividend

CORRECTION...by AmerisourceBergen Corporation

Business Wire

VALLEY FORGE, Pa. -- August 8, 2013

Fourth graph, payable date should read"September 3, 2013"(sted "September 4,
2013"), and stockholders of record date should read "August 19, 2013" (sted
"August 21, 2013").

The corrected release reads:

 AMERISOURCEBERGEN AUTHORIZES A NEW $750 MILLION SHARE REPURCHASE PROGRAM AND
                         APPROVES QUARTERLY DIVIDEND

The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC) today
authorized a new $750 million share repurchase program. AmerisourceBergen
expects to use the new program to repurchase its outstanding shares of common
stock, subject to market conditions. The Company has $446.1 million remaining
on its prior November 2012 authorization, bringing the total amount authorized
for repurchases to $1.2 billion. To date in fiscal year 2013, which ends
September 30, 2013, the Company has spent $401.1 million to repurchase its
outstanding shares of common stock.

“Our share repurchases during fiscal year 2013 and our new program demonstrate
our continued commitment to delivering long-term shareholder value,” said
Steven H. Collis, AmerisourceBergen President & Chief Executive Officer.
“While our expectations for share repurchases over the next few quarters have
not changed, the new authorization gives us significant longer-term
flexibility.”

AmerisourceBergen may repurchase its shares from time to time for cash in open
market transactions or by other means in accordance with applicable federal
securities laws. The Company currently has approximately 231 million common
shares outstanding.

In addition, the Board of Directors today declared a cash dividend of $0.21
per share on Common Stock, payable September 3, 2013, to stockholders of
record at the close of business on August 19, 2013.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in the
pharmaceutical supply channel, the Company provides drug distribution and
related services designed to reduce costs and improve patient outcomes.
AmerisourceBergen's service solutions range from niche premium logistics and
pharmaceutical packaging to reimbursement and pharmaceutical consulting
services. With over $80 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 13,000 people.
AmerisourceBergen is ranked #32 on the Fortune 500 list. For more information,
go to www.amerisourcebergen.com.

Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Words such as
“expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,”
“will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on
track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” ”possible,”
“assume,” variations of such words, and similar expressions are intended to
identify such forward-looking statements. These statements are based on
management's current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance and
are based on assumptions that could prove incorrect or could cause actual
results to vary materially from those indicated. Among the factors that could
cause actual results to differ materially from those projected, anticipated or
implied are the following: changes in pharmaceutical market growth rates; the
loss of one or more key customer or supplier relationships; changes in
customer mix; customer delinquencies, defaults or insolvencies; supplier
defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract or
other dispute with customers or suppliers; federal and state government
enforcement initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tam litigation for
alleged violations of fraud and abuse laws and regulations and/or any other
laws and regulations governing the marketing, sale, purchase, and/or
dispensing of pharmaceutical products or services and any related litigation,
including shareholder derivative lawsuits; changes in federal and state
legislation or regulatory action affecting pharmaceutical product pricing or
reimbursement policies, including under Medicaid and Medicare; changes in
regulatory or clinical medical guidelines and/or labeling for the
pharmaceutical products we distribute, including certain anemia products;
price inflation in branded pharmaceuticals and price deflation in generics;
greater or less than anticipated benefit from launches of the generic versions
of previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to realize
the anticipated benefits of the implementation of an enterprise resource
planning (ERP) system; interest rate and foreign currency exchange rate
fluctuations; risks associated with international business operations,
including non-compliance with the U.S. Foreign Corrupt Practices Act,
anti-bribery laws and economic sanctions and import laws and regulations;
economic, business, competitive and/or regulatory developments outside of the
United States; risks associated with the strategic, long-term relationship
among Walgreen Co., Alliance Boots GmbH, and AmerisourceBergen, the occurrence
of any event, change or other circumstance that could give rise to the
termination, cross-termination or modification of any of the transaction
documents among the parties (including, among others, the distribution
agreement or the generics agreement), an impact on our earnings per share
resulting from the issuance of the Warrants, an inability to realize
anticipated benefits (including benefits resulting from participation in the
Walgreens Boots Alliance Development GmbH joint venture), the disruption of
AmerisourceBergen’s cash flow and ability to return value to its stockholders
in accordance with its past practices, disruption of or changes in vendor,
payer and customer relationships and terms, and the reduction of
AmerisourceBergen’s operational, strategic or financial flexibility; the
acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; our inability to successfully
complete any other transaction that we may wish to pursue from time to time;
changes in tax laws or legislative initiatives that could adversely affect our
tax positions and/or our tax liabilities or adverse resolution of challenges
to our tax positions; increased costs of maintaining, or reductions in our
ability to maintain, adequate liquidity and financing sources; volatility and
deterioration of the capital and credit markets; and other economic, business,
competitive, legal, tax, regulatory and/or operational factors affecting our
business generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those described in
forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the
Company's Annual Report on Form 10-K for the fiscal year ended September 30,
2012 and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act of 1934. You are cautioned not
to place undue reliance on these forward-looking statements, which speak only
as of the date they are made. Except to the extent required by law,
AmerisourceBergen does not undertake, and expressly disclaims, any duty or
obligation to publicly update any forward-looking statement after the date of
this report, whether as a result of new information, future events, changes in
assumptions or otherwise.

Contact:

AmerisourceBergen Corporation
Barbara Brungess, 610-727-7199
bbrungess@amerisourcebergen.com
 
Press spacebar to pause and continue. Press esc to stop.